S. H. Hohnloser
About
In The Last Decade
S. H. Hohnloser
34 papers receiving 396 citations
Peers
Comparison fields: 5 of 47
- Cardiology and Cardiovascular Medicine 385
- Radiology, Nuclear Medicine and Imaging 37
- Surgery 28
- Molecular Biology 27
- Emergency Medicine 22
Countries citing papers authored by S. H. Hohnloser
This map shows the geographic impact of S. H. Hohnloser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. H. Hohnloser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. H. Hohnloser more than expected).
Fields of papers citing papers by S. H. Hohnloser
This network shows the impact of papers produced by S. H. Hohnloser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. H. Hohnloser. The network helps show where S. H. Hohnloser may publish in the future.
Co-authorship network of co-authors of S. H. Hohnloser
This figure shows the co-authorship network connecting the top 25 collaborators of S. H. Hohnloser. A scholar is included among the top collaborators of S. H. Hohnloser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. H. Hohnloser. S. H. Hohnloser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 8 | |
| 3 | Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation : Insights from the ARISTOTLE trial | 7 |
| 4 | Abstract 13026: Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE Trial | 2 |
| 5 | 29 | |
| 6 | 45 | |
| 7 | 7 | |
| 8 | 0 | |
| 9 | 29 | |
| 10 | 48 | |
| 11 | 31 | |
| 12 | 7 | |
| 13 | 18 | |
| 14 | 1 | |
| 15 | 3 | |
| 16 | 14 | |
| 17 | 2 | |
| 18 | 4 | |
| 19 | 2 | |
| 20 | [Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.